Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon

被引：4
作者：
Cabibbo, Giuseppe [1 ]
Celsa, Ciro [1 ,2 ]
Alimenti, Eleonora [3 ]
Iavarone, Massimo [4 ]
机构：
[1] Univ Palermo, Dept Hlth Promot Sci Maternal & Infant Care, Internal Med & Med Specialties, Sect Gastroenterol & Hepatol,PROMISE, Palermo, Italy
[2] Univ Palermo, Dept Surg Oncol & Oral Sci, Palermo, Italy
[3] Univ Pavia, Dept Med Sci, Pavia, Italy
[4] Ca Granda Osped Maggiore Policlin Milan, IRCCS Fdn, Div Gastroenterol & Hepatol, Milan, Italy
来源：
HEPATOLOGY | 2023年 / 77卷 / 04期
关键词：
D O I：
10.1097/HEP.0000000000000205
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1074 / 1077
页数：4
相关论文
共 17 条
[1]   Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA [J].
Abou-Alfa, Ghassan K. ;
Chan, Stephen Lam ;
Kudo, Masatoshi ;
Lau, George ;
Kelley, Robin Kate ;
Furuse, Junji ;
Sukeepaisarnjaroen, Wattana ;
Kang, Yoon-Koo ;
Dao, Tu V. ;
De Toni, Enrico N. ;
Rimassa, Lorenza ;
Breder, Valeriy Vladimirovich ;
Vasilyev, Alexander ;
Heurgue, Alexandra ;
Tam, Vincent ;
Mody, Kabir ;
Thungappa, Satheesh Chiradoni ;
He, Philip ;
Negro, Alejandra ;
Sangro, Bruno .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[2]  
[Anonymous], COMMON TERMINOLOGY C
[3]   Radiological endpoints as surrogates for survival benefit in hepatocellular carcinoma trials: All that glitters is not gold [J].
Cabibbo, Giuseppe ;
Bruix, Jordi .
JOURNAL OF HEPATOLOGY, 2023, 78 (01) :8-11
[4]   Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma [J].
Cabibbo, Giuseppe ;
Celsa, Ciro ;
Enea, Marco ;
Battaglia, Salvatore ;
Rizzo, Giacomo Emanuele Maria ;
Busacca, Anita ;
Matranga, Domenica ;
Attanasio, Massimo ;
Reig, Maria ;
Craxi, Antonio ;
Camma, Calogero .
CANCERS, 2021, 13 (01) :1-14
[5]   Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma [J].
Cabibbo, Giuseppe ;
Petta, Salvatore ;
Barbara, Marco ;
Attardo, Simona ;
Bucci, Laura ;
Farinati, Fabio ;
Giannini, Edoardo G. ;
Negrini, Giulia ;
Ciccarese, Francesca ;
Rapaccini, Gian Lodovico ;
Di Marco, Maria ;
Caturelli, Eugenio ;
Zoli, Marco ;
Borzio, Franco ;
Sacco, Rodolfo ;
Virdone, Roberto ;
Marra, Fabio ;
Mega, Andrea ;
Morisco, Filomena ;
Benvegnu, Luisa ;
Gasbarrini, Antonio ;
Svegliati-Baroni, Gianluca ;
Foschi, Francesco Giuseppe ;
Olivani, Andrea ;
Masotto, Alberto ;
Nardone, Gerardo ;
Colecchia, Antonio ;
Persico, Marcello ;
Craxi, Antonio ;
Trevisani, Franco ;
Camma, Calogero .
JOURNAL OF HEPATOLOGY, 2017, 67 (01) :65-71
[6]   Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis [J].
El Hajra, Ismael ;
Sanduzzi-Zamparelli, Marco ;
Sapena, Victor ;
Munoz-Martinez, Sergio ;
Mauro, Ezequiel ;
Llarch, Neus ;
Iserte, Gemma ;
Forner, Alejandro ;
Rios, Jose ;
Bruix, Jordi ;
Reig, Maria .
HEPATOLOGY, 2023, 77 (04) :1139-1149
[7]   Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Qin, Shukui ;
Ikeda, Masafumi ;
Galle, Peter R. ;
Ducreux, Michel ;
Kim, Tae-You ;
Kudo, Masatoshi ;
Breder, Valeriy ;
Merle, Philippe ;
Kaseb, Ahmed O. ;
Li, Daneng ;
Verret, Wendy ;
Xu, Derek-Zhen ;
Hernandez, Sairy ;
Liu, Juan ;
Huang, Chen ;
Mulla, Sohail ;
Wang, Yulei ;
Lim, Ho Yeong ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905
[8]   Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib [J].
Iavarone, Massimo ;
Cabibbo, Giuseppe ;
Biolato, Marco ;
Della Corte, Cristina ;
Maida, Marcello ;
Barbara, Marco ;
Basso, Michele ;
Vavassori, Sara ;
Craxi, Antonio ;
Grieco, Antonio ;
Camma, Carlo ;
Colombo, Massimo .
HEPATOLOGY, 2015, 62 (03) :784-791
[9]   Field-Practice Study of Sorafenib Therapy for Hepatocellular Carcinoma: A Prospective Multicenter Study in Italy [J].
Iavarone, Massimo ;
Cabibbo, Giuseppe ;
Piscaglia, Fabio ;
Zavaglia, Claudio ;
Grieco, Antonio ;
Villa, Erica ;
Camma, Calogero ;
Colombo, Massimo ;
Sangiovanni, Angelo ;
Vavassori, Sara ;
Romeo, Raffaella ;
Di Marco, Vito ;
Craxi, Antonio ;
Borghi, Alberto ;
Granito, Alessandro ;
Bolondi, Luigi ;
Airoldi, Aldo ;
Pinzello, Giovambattista ;
Biolato, Marco ;
Racco, Simona ;
Pompili, Maurizio ;
Lei, Barbara ;
De Maria, Nicola .
HEPATOLOGY, 2011, 54 (06) :2055-2063
[10]   CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis [J].
Kudo, Masatoshi ;
Matilla, Ana ;
Santoro, Armando ;
Melero, Ignacio ;
Gracian, Antonio Cubillo ;
Acosta-Rivera, Mirelis ;
Choo, Su-Pin ;
El-Khoueiry, Anthony B. ;
Kuromatsu, Ryoko ;
El-Rayes, Bassel ;
Numata, Kazushi ;
Itoh, Yoshito ;
Di Costanzo, Francesco ;
Crysler, Oxana ;
Reig, Maria ;
Shen, Yun ;
Neely, Jaclyn ;
Tschaika, Marina ;
Wisniewski, Tami ;
Sangro, Bruno .
JOURNAL OF HEPATOLOGY, 2021, 75 (03) :600-609
12